source
- EyePoint’s Phase 3 eye drug falls short of Eylea, stock tumbles 70%EyePoint reported that its experimental treatment for wet age-related macular degeneration did not meet the efficacy endpoints in a Phase 3 trial when compared with the current standard, Eylea. The…
- Tarsus Pharma to spend $450M upfront acquiring Alkeus to expand its ophthalmology pipelineTarsus Pharmaceuticals announced it will acquire Alkeus Pharmaceuticals, a Phase 3 biotech focused on a Stargardt disease drug, for an upfront payment of $450 million. The deal is intended to broad…